Biomerica (BMRA) Stock Price, News & Analysis

Company Overview

Biomerica, Inc. is a medical technology company that develops, manufactures and commercializes diagnostic and therapeutic products, with a primary focus on gastrointestinal disorders and other medical conditions. The company is headquartered in Irvine, California, and serves healthcare providers and patients in the United States and selected international markets through direct sales and distribution relationships.

Biomerica’s principal product is inFoods IBS, a diagnostic-guided dietary management program for irritable bowel syndrome. The program combines a blood-based test intended to identify foods that may contribute to an individual’s symptoms with a personalized dietary plan designed to help patients manage those symptoms. Biomerica has also developed and marketed diagnostic products addressing gastrointestinal and infectious-disease applications.

The company has historically focused on combining diagnostic testing with individualized treatment or dietary-management approaches. Zackary Irani serves as Biomerica’s president and chief executive officer and has been associated with the company’s leadership for several years.

Key Stats

• Today's Range: $2.30 to $2.52
• 50-Day Range: $1.49 to $2.51
• 52-Week Range: $1.45 to $3.21
• Volume: 75,411 shs
• Average Volume: 200,887 shs
• Market Capitalization: $7.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Sell

Biomerica Stock Analysis - MarketRank™

Biomerica scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biomerica has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Biomerica has a consensus price target of $9.00, representing about 258.6% upside from its current price of $2.51.

Amount of Analyst Coverage

Biomerica has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biomerica is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biomerica is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biomerica has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.28% of the float of Biomerica has been sold short.

Short Interest Ratio / Days to Cover

Biomerica has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biomerica has recently increased by 215.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomerica does not currently pay a dividend.

Dividend Growth

Biomerica does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for BMRA on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.5 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Biomerica in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $148,000.00 in company stock, which represents 1.9082% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Biomerica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $148,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

18.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.28% of the stock of Biomerica is held by institutions.

Company Calendar

• Last Earnings: 8/31/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 10/21/2026
• Fiscal Year End: 5/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:BMRA
• CIK: 73290
• Web: www.biomerica.com
• Phone: (949) 379-2875
• Fax: 949-553-1231
• Employees: 50
• Year Founded: 1971

Price Target and Rating

• Average Price Target for Biomerica: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +258.6%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.78 million
• Net Margins: -84.79%
• Pretax Margin: -84.26%
• Return on Equity: -97.19%
• Return on Assets: -61.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.62
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $4.45 million
• Price / Sales: 1.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 2.95

Miscellaneous

• Outstanding Shares: 3,090,000
• Free Float: 2,534,000
• Market Cap: $7.76 million
• Optionable: No Data
• Beta: 0.37